Skye Bioscience Inc.

NASDAQ: SKYE · Real-Time Price · USD
3.53
0.26 (7.95%)
At close: Aug 15, 2025, 3:59 PM
3.51
-0.57%
After-hours: Aug 15, 2025, 07:36 PM EDT

Skye Bioscience Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
298.64K 124.25K 115K 34.13K
Gross Profit
-298.64K -124.25K -115K -34.13K
Operating Income
-36.43M -13.67M -12.11M -7.85M
Interest Income
-3.03M 99.97K 19.01K 3.00
Pretax Income
-26.56M -37.64M -19.48M -8.52M
Net Income
-26.57M -37.65M -19.48M -8.52M
Selling & General & Admin
17.73M 7.73M 6.09M 4.92M
Research & Development
18.7M 5.82M 6.01M 2.93M
Other Expenses
-299.2K 1K -115.58K 1K
Operating Expenses
36.13M 13.55M 11.99M 7.85M
Interest Expense
749.31K 906.27K 665.13K 769.16K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
36.43M 13.67M 12.11M 7.85M
Income Tax Expense
10.07K 3.6K 6.74K 2.1K
Shares Outstanding (Basic)
36.49M 7.01M 1.98M 1.63M
Shares Outstanding (Diluted)
36.49M 7.01M 1.98M 1.65M
EPS (Basic)
-0.73 -5.37 -9.82 -5.24
EPS (Diluted)
-0.73 -5.37 -10 -5.24
EBITDA
-25.51M -36.61M -18.57M -7.72M
EBIT
-25.81M -36.73M -12.6M -7.75M
Depreciation & Amortization
298.64K 124.25K 115K 34.13K